JP2014198029A5 - - Google Patents

Info

Publication number

JP2014198029A5

JP2014198029A5 JP2013075428A JP2013075428A JP2014198029A5 JP 2014198029 A5 JP2014198029 A5 JP 2014198029A5 JP 2013075428 A JP2013075428 A JP 2013075428A JP 2013075428 A JP2013075428 A JP 2013075428A JP 2014198029 A5 JP2014198029 A5 JP 2014198029A5

Authority

JP

Japan

Prior art keywords

nucleic acid

acid amplification

amplification reaction

reagent

solid phase

Prior art date

2013-03-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000007523 nucleic acids Chemical class 0.000 claims description 29
• 238000003199 nucleic acid amplification method Methods 0.000 claims description 28
• 102000039446 nucleic acids Human genes 0.000 claims description 27
• 108020004707 nucleic acids Proteins 0.000 claims description 27
• 238000006243 chemical reaction Methods 0.000 claims description 26
• 230000003321 amplification Effects 0.000 claims description 25
• 239000003153 chemical reaction reagent Substances 0.000 claims description 17
• 239000007790 solid phase Substances 0.000 claims description 15
• 229920000858 Cyclodextrin Polymers 0.000 claims description 11
• 238000000034 method Methods 0.000 claims description 11
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 9
• 239000007788 liquid Substances 0.000 claims description 8
• 102100034343 Integrase Human genes 0.000 claims description 7
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 6
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 6
• 101710203526 Integrase Proteins 0.000 claims description 6
• 239000011230 binding agent Substances 0.000 claims description 5
• -1 hydroxypropyl group Chemical group 0.000 claims description 4
• 239000000243 solution Substances 0.000 claims description 4
• 239000012895 dilution Substances 0.000 claims description 2
• 238000010790 dilution Methods 0.000 claims description 2
• 239000002563 ionic surfactant Substances 0.000 claims 4
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
• 239000003945 anionic surfactant Substances 0.000 claims 2
• 238000007865 diluting Methods 0.000 claims 1
• 238000010438 heat treatment Methods 0.000 claims 1
• 238000010839 reverse transcription Methods 0.000 claims 1
• 229920002477 rna polymer Polymers 0.000 claims 1
• 239000000523 sample Substances 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 238000007397 LAMP assay Methods 0.000 description 2
• 230000000694 effects Effects 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
• 239000001116 FEMA 4028 Substances 0.000 description 1
• 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
• 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
• 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
• 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
• 229960004853 betadex Drugs 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
• 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
• 125000001183 hydrocarbyl group Chemical group 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 239000012488 sample solution Substances 0.000 description 1